Challenges in the use of NG2 antigen as a marker to predict MLL rearrangements in multi-center studies

Leuk Res. 2011 Aug;35(8):1001-7. doi: 10.1016/j.leukres.2011.03.006. Epub 2011 Mar 27.

Abstract

Rearrangements in MLL (MLL-r) are common within very young children with leukemia and affect the prognosis and treatment. Previous studies have suggested the use of the NG2 molecule as a marker for MLL-r but these studies were performed using a small number of infants. We analyzed 148 patients (all less than 24 months, 86 less than 12 months) from various centers in Brazil to determine the predictive power of NG2 within that cohort. We show that NG2 can be used for MLL-r prediction; however, proper staff training and standardized sampling procedures are essential when receiving samples from multiple centers as the accuracy of the prediction varies greatly on a per center basis.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens / genetics*
  • Female
  • Gene Rearrangement*
  • Histone-Lysine N-Methyltransferase
  • Humans
  • Immunophenotyping
  • Infant
  • Infant, Newborn
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / immunology
  • Male
  • Myeloid-Lymphoid Leukemia Protein / genetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Prognosis
  • Proteoglycans / genetics*
  • ROC Curve
  • Sensitivity and Specificity

Substances

  • Antigens
  • KMT2A protein, human
  • Proteoglycans
  • chondroitin sulfate proteoglycan 4
  • Myeloid-Lymphoid Leukemia Protein
  • Histone-Lysine N-Methyltransferase